The monofunctional platinum(II) compounds, phenanthriplatin and pyriplatin, modulate apoptosis signaling pathways in HEI-OC1 auditory hybridoma cells

Monroe, Jerry D.; Johnston, Alexandra M.; Smith, Michael E.

doi:10.1016/j.neuro.2020.04.005

Cited by 6 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HEI-OC1 cells are also an excellent test bed for development of less ototoxic variants of essential drugs. A particularly interesting study used HEI-OC1 cells to determine the relative toxicity of platinum-based anti-cancer compounds, with the goal of developing a less toxic version of cisplatin ( 115 ). Unfortunately, Monroe et al ( 115 ) found that the monofunctional platinum (II) compounds phenathriplatin and pyriplatin were as cytotoxic to HEI-OC1 cells as cisplatin ( 115 ).…”

Section: Models For Ototoxicity Studiesmentioning

confidence: 99%

“…A particularly interesting study used HEI-OC1 cells to determine the relative toxicity of platinum-based anti-cancer compounds, with the goal of developing a less toxic version of cisplatin ( 115 ). Unfortunately, Monroe et al ( 115 ) found that the monofunctional platinum (II) compounds phenathriplatin and pyriplatin were as cytotoxic to HEI-OC1 cells as cisplatin ( 115 ). While these results did not lead to chemotherapy agents with lower ototoxic potential, they highlight the strengths of cochlear cell lines for rapid determination of potential ototoxicity before candidate therapeutics are tested clinically.…”

Section: Models For Ototoxicity Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Detecting Novel Ototoxins and Potentiation of Ototoxicity by Disease Settings

Coffin

Boney²,

Hill

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

Over 100 drugs and chemicals are associated with permanent hearing loss, tinnitus, and vestibular deficits, collectively known as ototoxicity. The ototoxic potential of drugs is rarely assessed in pre-clinical drug development or during clinical trials, so this debilitating side-effect is often discovered as patients begin to report hearing loss. Furthermore, drug-induced ototoxicity in adults, and particularly in elderly patients, may go unrecognized due to hearing loss from a variety of etiologies because of a lack of baseline assessments immediately prior to novel therapeutic treatment. During the current pandemic, there is an intense effort to identify new drugs or repurpose FDA-approved drugs to treat COVID-19. Several potential COVID-19 therapeutics are known ototoxins, including chloroquine (CQ) and lopinavir-ritonavir, demonstrating the necessity to identify ototoxic potential in existing and novel medicines. Furthermore, several factors are emerging as potentiators of ototoxicity, such as inflammation (a hallmark of COVID-19), genetic polymorphisms, and ototoxic synergy with co-therapeutics, increasing the necessity to evaluate a drug's potential to induce ototoxicity under varying conditions. Here, we review the potential of COVID-19 therapies to induce ototoxicity and factors that may compound their ototoxic effects. We then discuss two models for rapidly detecting the potential for ototoxicity: mammalian auditory cell lines and the larval zebrafish lateral line. These models offer considerable value for pre-clinical drug development, including development of COVID-19 therapies. Finally, we show the validity of in silico screening for ototoxic potential using a computational model that compares structural similarity of compounds of interest with a database of known ototoxins and non-ototoxins. Preclinical screening at in silico, in vitro, and in vivo levels can provide an earlier indication of the potential for ototoxicity and identify the subset of candidate therapeutics for treating COVID-19 that need to be monitored for ototoxicity as for other widely-used clinical therapeutics, like aminoglycosides and cisplatin.

show abstract

Section: Models For Ototoxicity Studiesmentioning

confidence: 99%